Press Releases March 29, 2026 08:00 PM

OR Royalties Files 2025 Year-End Disclosure Documents

OR Royalties files comprehensive 2025 year-end disclosure documents with Canadian and US regulators

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
OR

OR Royalties Inc., a precious metals royalty and streaming company, has filed its Annual Information Form, Consolidated Annual Financial Statements, Management's Discussion and Analysis for the fiscal year ended December 31, 2025, along with its Annual Report on Form 40-F with the SEC. The filings include detailed financial and operational information and are accessible to shareholders and the public.

OR Royalties Files 2025 Year-End Disclosure Documents
OR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • OR Royalties operates primarily in Tier-1 mining jurisdictions including Canada, the US, and Australia.
  • The company manages a portfolio of over 195 royalties, streams, and similar interests focused on precious metals.
  • Their cornerstone asset is a net smelter return royalty on the Canadian Malartic Complex, one of the world's largest gold mines, owned by Agnico Eagle Mines Limited.

MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) -- OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX & NYSE) announces that its Annual Information Form, Consolidated Annual Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2025 have been filed with Canadian securities regulatory authorities.  OR Royalties has also filed its Annual Report on Form 40-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission.  Copies of these documents may be obtained via www.sedarplus.ca, www.sec.gov (for the Form 40-F) or www.ORroyalties.com.

Shareholders may also receive hard copies of these documents without charge upon request to OR Royalties’ Investor Relations Department, 1100 av. des Canadiens-de-Montréal, Suite 300, P.O. Box 211, Montreal, Québec, Canada H3B 2S2, or to [email protected].

About OR Royalties Inc.

OR Royalties is a precious metals royalty and streaming company focused on Tier-1 mining jurisdictions defined as Canada, the United States, and Australia. OR Royalties commenced activities in June 2014 with a single producing asset, and today holds a portfolio of over 195 royalties, streams and similar interests. OR Royalties’ portfolio is anchored by its cornerstone asset, the 3-5% net smelter return royalty on Agnico Eagle Mines Limited’s Canadian Malartic Complex, one of the world’s largest gold mines.

OR Royalties’ head office is located at 1100 Avenue des Canadiens-de-Montréal, Suite 300, Montréal, Québec, H3B 2S2.

For further information, please contact OR Royalties Inc.:Grant Moenting
Vice President, Capital Markets
Cell: (365) 275-1954
Email: [email protected] Taylor
Vice President, Sustainability and Communications
Tel: (647) 477-2087
Email: [email protected]

 


Risks

  • Exposure to fluctuations in precious metals markets can impact royalty income and company valuation.
  • Dependence on the performance and production levels of mines within their royalty portfolio, such as the Canadian Malartic Complex.
  • Potential regulatory and geopolitical risks inherent in operating across multiple international mining jurisdictions.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026